Synopsis: Fluticasone furoate-vilanterol has previously been shown to be comparable to existing therapies with regard to improvements in forced Expiratory volume in 1 sec. This study demonstrates that fluticasone furoate-vilanterol reduces Chronic Obstructive Pulmonary Disease exacerbations compared with usual care when studied in a real-world primary care setting.
Source: Vestbo J, Leather D, Bakerly ND, New J et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016.
Disclosure: The authors declare that they have no conflicts of interest.